Establishment Labs Reports 45% Revenue Growth in Q1 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Source: Yahoo Finance
- Strong Revenue Growth: Establishment Labs Holdings Inc reported $59.9 million in revenue for Q1 2026, reflecting a 45% year-over-year increase, indicating robust market performance and growth potential.
- Exceptional U.S. Performance: The U.S. business experienced a remarkable 216% revenue growth, primarily driven by the successful launch of the Motiva platform, showcasing rapid market penetration and increased customer acceptance.
- Improved Gross Margin: Gross margin improved by 350 basis points to 70.7%, reflecting enhanced operational efficiency and increased sales of higher-margin products, which further strengthens the company's profitability.
- Raised Full-Year Guidance: The company raised its full-year revenue guidance to $266.5 million to $268.5 million, demonstrating confidence in continued growth despite geopolitical uncertainties and ongoing financial pressures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ESTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ESTA
Wall Street analysts forecast ESTA stock price to fall
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 91.040
Low
75.00
Averages
82.88
High
90.00
Current: 91.040
Low
75.00
Averages
82.88
High
90.00
About ESTA
Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
JW Asset Management Sells Shares of Establishment Labs Holdings
- Significant Transaction Size: JW Asset Management's indirect sale of 90,533 shares of Establishment Labs from May 26 to May 28, 2026, totaled approximately $6.64 million, exceeding its historical average sale size by 3.6 times, indicating a strategic market timing.
- Change in Holdings: Post-transaction, JW Asset Management no longer holds direct shares in Establishment Labs but retains 2,890,582 shares indirectly, reflecting continued confidence in the company despite falling below the 10% ownership threshold.
- Positive Market Reaction: At the time of the sale, Establishment Labs' stock price had surged from a 52-week low of $33.35 in 2025 to $73.31, and it reached a 52-week high of $90.50 in June, showcasing the company's strong market performance.
- Strong Financial Performance: Establishment Labs reported a remarkable 45% year-over-year revenue growth in Q1, reaching $59.9 million, prompting an upward revision of its full-year guidance for 2026, further solidifying investor confidence in its growth prospects.
See More
JW Asset Management Reduces Stake in Establishment Labs
- Share Reduction Details: JW Asset Management sold 90,533 shares of Establishment Labs between May 26 and May 28, 2026, generating approximately $6.64 million at an average price of $73.31 per share, reducing its indirect holdings to 2.89 million shares, indicating a cautious stance towards the company's future.
- Ownership Percentage Change: This transaction decreased JW Asset Management's indirect ownership from about 3.04% to 2.98%, marking its exit from being a 10% shareholder, reflecting its adaptation and adjustment to market dynamics.
- Company Performance: Establishment Labs achieved a remarkable 45% year-over-year growth in Q1 2026, with revenues reaching $59.9 million, prompting an upward revision of its full-year guidance, showcasing strong growth potential in the medical devices sector.
- Market Reaction and Outlook: Despite the share reduction, JW Asset Management retains nearly three million shares, indicating a long-term bullish outlook on Establishment Labs, especially after the stock price reached a 52-week high of $90.50 in June, leading investors to remain optimistic about its future performance.
See More
Hedge Fund Sells $6.6 Million in Establishment Labs Shares
- Significant Transaction Size: JW Asset Management indirectly sold 90,533 shares of Establishment Labs between May 26 and May 28, 2026, totaling approximately $6.64 million, indicating a strategic reduction in their holdings.
- Change in Holdings: Post-transaction, JW Asset Management disclosed no direct holdings in Establishment Labs but continues to hold 2,890,582 shares indirectly, reflecting ongoing interest and confidence in the company.
- Historical Trade Comparison: The 90,533 shares sold exceeded JW Asset Management's average historical sale size of 25,263 shares, suggesting a more aggressive divestment strategy in response to market conditions.
- Market Reaction and Outlook: Despite the sale, Establishment Labs' stock price reached a 52-week high of $90.50 in June 2026, indicating strong market optimism for the company's future growth, particularly after reporting a 45% year-over-year revenue increase in Q1.
See More
Conexeu Sciences Targets GLP-1 Aesthetics Market with Innovative Platform
- Market Validation: Galderma's presentation of clinical data on its injectables (Sculptra, Restylane) addressing medication-induced facial volume loss signifies that the 'Ozempic face' category has gained formal recognition, catalyzing rapid growth in the aesthetics industry.
- Surge in Patient Demand: In 2024, U.S. plastic surgeons treated over 837,000 GLP-1 patients, indicating a swift rise in demand for facial restoration, which highlights the substantial potential and business opportunities within this emerging market.
- Technological Innovation: Conexeu's CXU™ platform features a thermosensitive collagen scaffold designed for tissue regeneration rather than mere filling, with a targeted FDA 510(k) submission planned for early 2027, which could open new market avenues for the company if successful.
- Competitive Landscape: As a newly public entity, Conexeu faces competition from established players like Galderma, yet its unique regenerative technology may allow it to carve out a niche in the rapidly expanding aesthetics market.
See More
Establishment Labs to Join Russell 2000 Index
- Inclusion in Russell 2000: Establishment Labs (ESTA) will be added to the US small-cap Russell 2000 Index as part of the 2026 Russell indexes reconstitution, effective June 29, 2026, which is expected to enhance the company's market visibility and attract investor interest.
- Revenue Forecast Increase: The company targets a revenue range of $266.5 million to $268.5 million for 2026, reflecting a rise in minimally invasive revenue forecasts exceeding $35 million, indicating strong growth potential in the medical device market.
- Quant Rating Improvement: Seeking Alpha's Quant Rating highlights Establishment Labs as a strong performer in foreign healthcare, further boosting investor confidence and potentially attracting more institutional investors to the stock.
- Historical Earnings Data: The historical earnings data for Establishment Labs provides crucial financial context for investors, aiding in the assessment of the company's long-term growth potential and market performance, which will play a key role in future investment decisions.
See More
Conexeu Sciences Expands Board to Support Commercialization Efforts
- Board Expansion: On June 15, 2026, Conexeu Sciences Inc. expanded its board from six to nine members, with new directors primarily from Fortune 500 companies, signaling the company's ambition to transition its cutting-edge tissue regeneration technology into a viable business.
- Executive Appointment: Co-founder David Bogart was promoted to Chief Commercial Officer, overseeing over $75 million in capital formation, indicating Conexeu's focus on commercial strategy and market outreach to lay the groundwork for future growth.
- Technology Platform: Conexeu's CXU™ platform is a bioregenerative extracellular matrix that rapidly transitions into a stable gel scaffold at body temperature, expected to target multiple billion-dollar markets including advanced wound care and medical aesthetics, showcasing its broad market potential.
- Market Outlook: With an aging population and the diabetes epidemic, the field of tissue regeneration is experiencing strong market momentum, and while Conexeu faces challenges from larger competitors, its unique technology and leadership team position it well for future success.
See More
JW Asset Management Sells Shares of Establishment Labs Holdings
- Significant Transaction Size: JW Asset Management's indirect sale of 90,533 shares of Establishment Labs from May 26 to May 28, 2026, totaled approximately $6.64 million, exceeding its historical average sale size by 3.6 times, indicating a strategic market timing.
- Change in Holdings: Post-transaction, JW Asset Management no longer holds direct shares in Establishment Labs but retains 2,890,582 shares indirectly, reflecting continued confidence in the company despite falling below the 10% ownership threshold.
- Positive Market Reaction: At the time of the sale, Establishment Labs' stock price had surged from a 52-week low of $33.35 in 2025 to $73.31, and it reached a 52-week high of $90.50 in June, showcasing the company's strong market performance.
- Strong Financial Performance: Establishment Labs reported a remarkable 45% year-over-year revenue growth in Q1, reaching $59.9 million, prompting an upward revision of its full-year guidance for 2026, further solidifying investor confidence in its growth prospects.
See More
JW Asset Management Reduces Stake in Establishment Labs
- Share Reduction Details: JW Asset Management sold 90,533 shares of Establishment Labs between May 26 and May 28, 2026, generating approximately $6.64 million at an average price of $73.31 per share, reducing its indirect holdings to 2.89 million shares, indicating a cautious stance towards the company's future.
- Ownership Percentage Change: This transaction decreased JW Asset Management's indirect ownership from about 3.04% to 2.98%, marking its exit from being a 10% shareholder, reflecting its adaptation and adjustment to market dynamics.
- Company Performance: Establishment Labs achieved a remarkable 45% year-over-year growth in Q1 2026, with revenues reaching $59.9 million, prompting an upward revision of its full-year guidance, showcasing strong growth potential in the medical devices sector.
- Market Reaction and Outlook: Despite the share reduction, JW Asset Management retains nearly three million shares, indicating a long-term bullish outlook on Establishment Labs, especially after the stock price reached a 52-week high of $90.50 in June, leading investors to remain optimistic about its future performance.
See More
Hedge Fund Sells $6.6 Million in Establishment Labs Shares
- Significant Transaction Size: JW Asset Management indirectly sold 90,533 shares of Establishment Labs between May 26 and May 28, 2026, totaling approximately $6.64 million, indicating a strategic reduction in their holdings.
- Change in Holdings: Post-transaction, JW Asset Management disclosed no direct holdings in Establishment Labs but continues to hold 2,890,582 shares indirectly, reflecting ongoing interest and confidence in the company.
- Historical Trade Comparison: The 90,533 shares sold exceeded JW Asset Management's average historical sale size of 25,263 shares, suggesting a more aggressive divestment strategy in response to market conditions.
- Market Reaction and Outlook: Despite the sale, Establishment Labs' stock price reached a 52-week high of $90.50 in June 2026, indicating strong market optimism for the company's future growth, particularly after reporting a 45% year-over-year revenue increase in Q1.
See More
Conexeu Sciences Targets GLP-1 Aesthetics Market with Innovative Platform
- Market Validation: Galderma's presentation of clinical data on its injectables (Sculptra, Restylane) addressing medication-induced facial volume loss signifies that the 'Ozempic face' category has gained formal recognition, catalyzing rapid growth in the aesthetics industry.
- Surge in Patient Demand: In 2024, U.S. plastic surgeons treated over 837,000 GLP-1 patients, indicating a swift rise in demand for facial restoration, which highlights the substantial potential and business opportunities within this emerging market.
- Technological Innovation: Conexeu's CXU™ platform features a thermosensitive collagen scaffold designed for tissue regeneration rather than mere filling, with a targeted FDA 510(k) submission planned for early 2027, which could open new market avenues for the company if successful.
- Competitive Landscape: As a newly public entity, Conexeu faces competition from established players like Galderma, yet its unique regenerative technology may allow it to carve out a niche in the rapidly expanding aesthetics market.
See More
Establishment Labs to Join Russell 2000 Index
- Inclusion in Russell 2000: Establishment Labs (ESTA) will be added to the US small-cap Russell 2000 Index as part of the 2026 Russell indexes reconstitution, effective June 29, 2026, which is expected to enhance the company's market visibility and attract investor interest.
- Revenue Forecast Increase: The company targets a revenue range of $266.5 million to $268.5 million for 2026, reflecting a rise in minimally invasive revenue forecasts exceeding $35 million, indicating strong growth potential in the medical device market.
- Quant Rating Improvement: Seeking Alpha's Quant Rating highlights Establishment Labs as a strong performer in foreign healthcare, further boosting investor confidence and potentially attracting more institutional investors to the stock.
- Historical Earnings Data: The historical earnings data for Establishment Labs provides crucial financial context for investors, aiding in the assessment of the company's long-term growth potential and market performance, which will play a key role in future investment decisions.
See More
Conexeu Sciences Expands Board to Support Commercialization Efforts
- Board Expansion: On June 15, 2026, Conexeu Sciences Inc. expanded its board from six to nine members, with new directors primarily from Fortune 500 companies, signaling the company's ambition to transition its cutting-edge tissue regeneration technology into a viable business.
- Executive Appointment: Co-founder David Bogart was promoted to Chief Commercial Officer, overseeing over $75 million in capital formation, indicating Conexeu's focus on commercial strategy and market outreach to lay the groundwork for future growth.
- Technology Platform: Conexeu's CXU™ platform is a bioregenerative extracellular matrix that rapidly transitions into a stable gel scaffold at body temperature, expected to target multiple billion-dollar markets including advanced wound care and medical aesthetics, showcasing its broad market potential.
- Market Outlook: With an aging population and the diabetes epidemic, the field of tissue regeneration is experiencing strong market momentum, and while Conexeu faces challenges from larger competitors, its unique technology and leadership team position it well for future success.
See More
